GLP-1 Drugs GLP-1 Medications Wegovy Semaglutide GLP-1 Agonists Ozempic Mounjaro GLP-1 Receptor Agonists Novo Nordisk Zepbound Tirzepatide Market Trends Clinical Trials Eli Lilly GLP-1 Treatments FDA Approvals Market Competition GLP-1s GLP-1 Petrelintide Insurance Coverage Drug Development Semaglutide and Tirzepatide Tirzepatide vs. Semaglutide Comparison Effectiveness Studies Clinical Studies Tirzepatide (Zepbound) Cost Barriers GLP-1 Products Regulatory Issues Prescription Medications Regulation Approval and Availability Drug Safety Viking Therapeutics Diabetes Treatments Challenges Amycretin Consumer Access Cost Reduction and Access Side Effects Incretin Drugs Mental Health Metsera Market Availability Survodutide GLP Inhibitors Obesity Treatments Financial Barriers
New oral drugs and cheaper generics are driving interest while cost, injection aversion, uncertain long‑term effects and high payer bills are prompting cautious prescribing and tighter employer coverage.
